Wearable sensors to track walking and involuntary movements in Huntington's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This longitudinal observational study uses wearable devices (ActiGraph LEAP and Axivity AX6) to passively monitor gait and chorea over repeated virtual visits. Participants complete four virtual visits with survey questions about movement and cognition, perform in-home movement assessments, and join interviews about how gait and chorea affect daily life. Care partners also take part in interviews to map symptoms and provide qualitative context about meaningful impacts. The protocol may be extended to annual visits for up to three years to examine change over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Inclusion Criteria for participants with adult-onset HD:

* Age of 25-65 years.
* Genetically confirmed HD with CAG \>= 40 (HD-ISS Stage 2 or mild/moderate Stage 3)
* English speaking.

Inclusion Criteria for control participants:

* Age of 25-65 years.
* English speaking.

Inclusion Criteria for support persons:

* Self-identified support person or family member of the enrolled participants with HD.
* 18 years or older
* English speaking.

Exclusion Criteria:

* Diagnosis of juvenile-onset HD.
* History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe
* Traumatic Brain Injury.
* Use of an assistive device for ambulation.
* Montreal Cognitive Assessment (MoCA) score of 18 or lower
* Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,
* cardiovascular or psychiatric disease.
* Pregnancy
* Cannot be enrolled into a blinded intervention trial at Baseline

Where it's running

• University of Rochester Medical Center
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Sugitha Maheswaran, BS
• Email: Sugi_maheswaran@urmc.rochester.edu
• Phone: 5857040344

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pridopidine for Huntington's Disease: a 1-year, randomized, placebo-controlled study

  This trial tests whether pridopidine can slow the progression of Huntington's disease in adults compared with placebo over one year.

  Recruiting at 17 sites Phase 3 Prilenia · Birmingham, Alabama and 65 other locations · NCT07609108

• Low-intensity focused ultrasound targeting the globus pallidus to improve movement in Huntington's disease

  This trial tests whether different pulse frequencies of low-intensity focused ultrasound (LIFU) aimed at a deep brain target can safely reduce chorea and other motor symptoms in adults with Huntington's disease.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07513844

• Safety and tolerability of human neural stem cell implants for Huntington's disease

  This research will test whether an implant of hNSC-01 human neural stem cells is safe and tolerable for adults with Huntington's disease.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California · NCT07451613

• SKY-0515 for adults with Huntington's disease

  This trial will test whether the oral drug SKY-0515 can lower harmful huntingtin protein and improve symptoms in adults aged 25 and older with genetically confirmed Huntington's disease.

  Recruiting at 19 sites Phase 2/3 Skyhawk Therapeutics, Inc. · Englewood, Colorado and 30 other locations · NCT07378644

• Votoplam for adults with early symptomatic Huntington's disease

  This trial will test whether votoplam (HTT227) is safe and can slow disease progression in adults with early symptomatic Huntington's disease.

  Recruiting at 117 sites Phase 3 Novartis · Birmingham, Alabama and 116 other locations · NCT07326709

• Comparing three social cognition tests in adults with early Huntington disease

  This project will test whether the DMASC-MC and two established social cognition tests can detect social thinking problems in adults with early Huntington disease.

  Recruiting Region Skane · Lund · NCT07253038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.